Evotec’s latest white paper shows how in vitro PK/PD modelling, powered by the Hollow Fibre Infection Model (HFIM), is redefining how novel anti-infectives are developed.
This cutting-edge approach enables smarter decisions, faster timelines, and better outcomes for patients—while minimizing the risk of resistance.

Key insights you’ll discover:

• How detailed PK/PD relationships guide optimal dosing to maximize efficacy and suppress resistance
• Why the HFIM can replicate human drug exposure profiles more accurately than traditional models
• How long-duration experiments in HFIM reveal resistance risks invisible to static assays
• Case studies showing HFIM’s role in developing antibiotic combinations against MDR pathogens
• How Evotec’s integrated HFIM platform and unique EvostrAIn™ collection accelerate antimicrobial programs from discovery to clinical use

If you’re serious about staying ahead in the fight against AMR, you can’t afford to miss this.
Download the paper to see how precision PK/PD insights are reshaping anti-infective development—making the difference between clinical success and failure.